Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benefits and Risks of Early Antiretroviral Treatment Initiation and 6-Months Isoniazid Prophylaxis in HIV-Infected West African Adults : a Randomized Factorial Trial (ANRS 12136 TEMPRANO)

X
Trial Profile

Benefits and Risks of Early Antiretroviral Treatment Initiation and 6-Months Isoniazid Prophylaxis in HIV-Infected West African Adults : a Randomized Factorial Trial (ANRS 12136 TEMPRANO)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Isoniazid; Lopinavir/ritonavir
  • Indications HIV-1 infections; HIV-2 infections; Tuberculosis
  • Focus Therapeutic Use
  • Acronyms TEMPRANO
  • Most Recent Events

    • 26 Jul 2017 Results assessing association between HIV-1-DNA and mortality in HIV-infected adults presented at the 9th International AIDS Society Conference on HIV Science
    • 26 Jul 2017 Results assessing association between inflammatory/coagulation biomarkers and mortality in HIV-infected adults with high CD4 counts presented at the 9th International AIDS Society Conference on HIV Science
    • 02 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top